Stelara Approved for Moderate-to-Severe Crohn’s Disease in Adults

Why I Won’t Get the Genetic Test for Breast Cancer
October 12, 2016
What’s the Connection between Night Sweats and Cancer? 
October 13, 2016
Show all

Stelara Approved for Moderate-to-Severe Crohn’s Disease in Adults

The medication Stelara was recently approved by the FDA to treat moderate-to-severe active Crohn’s disease.

Janssen Biotech recently announced that the company’s Stelara (ustekinumab) for the treatment of moderate-to-severe active Crohn’s disease in adults, has been approved by the U.S. Food and Drug Administration (FDA).

Stelara is the first approved biologic treatment for Crohn’s that targets interleukin (IL)-12 and IL-23 cytokines — which are known to play a critical role in immune and inflammatory responses.

Use is restricted to patients who either failed completion or were intolerant to treatment with immunomodulators or corticosteroids – but who never failed treatment with tumor necrosis factor (TNF) blockers or, who failed completion or were intolerant to treatment with one or more TNF blockers.

The approval was based on results from a clinical trial program that included three pivotal clinical studies in 1,300 patients:

  • The UNITI-1 induction study (NCT01369329) found that Stelara was capable of inducing clinical response and remission in patients who had previously failed or were intolerant to treatment with one or more TNF blockers. Study results showed that 34% of patients reported relief from Crohn’s disease symptoms six weeks after receiving a one-time intravenous (IV) infusion of Stelara.
  • The UNITI-2 induction study (NCT01369342) showed that Stelara induced remission in patients who had previously failed or were intolerant to conventional therapy with immunomodulators or corticosteroids, the majority of whom had never received treatment with TNF blockers. Relief from Crohn’s symptoms was reported in 56 percent of patients six weeks after the IV infusion.
  • The IM-UNITI maintenance study (NCT01369355) evaluated patients who achieved clinical response eight weeks after a single IV infusion of Stelara in the two UNITI-1 and UNITI-2 Phase 3 trials. Over 50% of patients receiving Stelara by injection every eight weeks were in clinical remission after almost one year after beginning treatment.

Read Full Article: Stelara Approved for Moderate-to-Severe Crohn’s Disease in Adults

Read Full Article: Stelara Approved for Moderate-to-Severe Crohn’s Disease in Adults

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.